Phase 3 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with Alzheimer's disease according to 2024 Alzheimer's Association standards, confirmed through brain imaging (amyloid PET scan) or specific protein measurements in blood or spinal fluid using an approved diagnostic test.
- People who score 24 or below on a standard memory and thinking test called the Mini-Mental State Examination (MMSE) at the start of the trial.
- People who have an identified caregiver who spends around 8 hours per week with them, and who is willing to attend all trial visits, help with medication, and take part in study assessments.
- People who have a history of agitation (as defined by an international medical organisation called the IPA) that began at least two weeks before the trial screening visit.
- People whose agitation and aggression scores meet a minimum threshold on two specific rating scales (NPI/NPI-NH and CMAI-IPA) at both the screening and baseline visits.
Who may not be able to join:
- People whose agitation appears to be caused by something other than their Alzheimer's disease.
- People with a history of bipolar disorder, schizophrenia, or schizoaffective disorder.
- People who have, or are considered at high risk of having, problems with urinary retention, stomach retention, or a specific type of eye condition called narrow-angle glaucoma (confirm with trial site).
- People considered by the investigating doctor to be at risk of suicidal behaviour during the study.
- People who have recently taken certain medications, including MAO inhibitors, some anti-seizure medications, mood stabilisers, or tricyclic antidepressants — though some antidepressants (such as SSRIs or SNRIs) taken at a stable dose for at least 8 weeks before screening may be permitted, as may certain sleep or agitation medications started at least 8 weeks prior (confirm with trial site).
- Additional criteria set out in the study protocol may also apply (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline on the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score at Week 14
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.